The bar for product differentiation and commercial viability has never been higher. Efficiency, external collaboration, and ...

Now is the time for leaders in Washington to act to protect patients, safeguard innovation, and strengthen our economy, ...

For small and midsize radiopharmaceutical developers, an experienced commercial partner can make or break the success of new ...

October is World Blindness Awareness Month, and patients with ultra-rare eye diseases are in desperate need of a new drug ...

Life science leaders with rounded corners lead to more enduring progress than razor-sharp perfection ever could, writes Tara ...

This article is the third and final installment of a three-part series aimed at helping drug and device manufacturers better navigate the VA and DoD health systems. Click here to read part one of the ...

Policy pressure, affordability gaps, and consumer expectations are reshaping how pharma companies think about direct to patient access. The question is no longer if, but how. Pharmaceutical companies ...

This article addresses the persistent challenge of high-volume patient enrollment in clinical research, which often impedes medical progress by delaying studies and increasing costs. Traditional ...

Early-stage companies thrive on being nimble and running rather than walking. In times when funding is flowing and the IPO market is open, early partnering may be viewed with some skepticism out of ...

In today’s competitive drug development landscape, the choice of a clinical research organization (CRO) can define a biotech’s trajectory. A CRO is more than an outsourced service provider—it is an ...

Delivering reliable, high-quality software at speed requires more than fast coding—it demands a smarter approach to testing. That’s where the Shift-Left methodology comes in. By moving testing ...